News >

Expert Highlights CAR T-Cell Breakthroughs

Angelica Welch
Published: Wednesday, Nov 01, 2017

David Maloney, MD, PhD
David Maloney, MD, PhD
The oncology community saw the first FDA approval of a chimeric antigen receptor (CAR) T-cell therapy in August 2017, when tisagenlecleucel (Kymriah) was approved for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refectory or in second or later relapse.

The FDA recently approved a second CAR T-cell therapy, the CD19-directed axicabtagene ciloleucel (Yescarta) as a treatment for adults with relapsed or refractory non-Hodgkin lymphoma.

In an interview with OncLive that was conducted between the time of these 2 approvals, David G. Maloney, MD, PhD, a member of the Clinical Research Division, Fred Hutchinson Cancer Research Center, discussed the progress made with CAR T cells, as well as the challenges that still exist in the use of this therapy.

OncLive: Can you discuss the success that has been seen with CAR T-cell therapy in ALL?

Maloney: We are doing most of our research in CAR T cells, and that is what I am the most interested in. The process for a CAR gene-modified T cell is that we take out a patient’s normal resting T cells and separate them in the laboratory into different populations and transduce them with a lentivirus expressing a CAR. That CAR gene now makes an antibody transgene on the cell surface that can then bind the T cell to whatever the target is. 

Therefore, the success has been with CD19, but there has also been some success with CD20 and CD22 reported in the past. We have treated many patients at Fred Hutchinson Cancer Research Center and there are several companies. Novartis…has…received FDA approval for tisagenlecleucel, so that is tremendously exciting for the field.

T cells are generally separated from the patient’s blood, sent to a center for production, they return in 3 to 4 weeks, then are given back to the patient upon completing chemotherapy—which is done to make space for the CAR T cells and provide an environment for the T cells to proliferate. They then are a living therapy—they replicate, multiply, and attack the tumor. They are remarkably potent; complete remission rates are in the 90% range in refractory ALL, which is just tremendously exciting. However, they are also pretty toxic. 

Cytokine release syndrome (CRS) is kind of a new thing that we must watch for. That can be treated with IL-6 receptor blockade with agents, such as tocilizumab and siltuximab, and often with steroids.

The second major toxicity is a neurotoxicity that can occur after the development of CRS 3 to 4 days later. It is very strange; I have patients develop an expressive aphasia with word-finding problems, which can progress to a coma or, rarely, a cerebral edema and patients can die. There is a low risk of dying from CAR T cells, but it is probably in the 1% to 3% range. These agents are the most potent things we have ever seen, and that is why the field is so excited about it.

However, there is a huge number of challenges. The FDA approved tisagenlecleucel for pediatric young adult ALL through 25 years old, which is difficult to understand. Therefore, technically, a 26-year-old would not be able to get this? We have got to fix that.

Obviously, we are doing studies in adults, as well. Toxicities are probably a little greater, but [it is] probably manageable. It is personalized medicine; the manufacturer now has to be in line with the patient to be able to make a product from that patient's cells. You clearly need an experienced team to be able to deal with CRS, and you need an intensive care unit (ICU) team to be able to take care of these patients when they get sick. Overall, [it is] a very exciting time, and now we are trying to translate it to other cancers—breast cancer, lung cancer, and other hematologic malignancies.

Let’s continue on that statement. Could the successes that we have seen with CAR T-cell therapies in ALL be translated to other malignancies?

It will be translated, but each [disease is different]. Antibody-drug conjugates are being used in other diseases already, and bispecific antibodies are not clear—they are active in lymphoma but we are unsure about solid cancers. In solid malignancies, CAR T cells have not been very effective to date; however, the studies are very, very limited at this point. The environment is very inhospitable for CAR T cells in a tumor mass; we are not even sure if they can get in there.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x